CAR T cell products
What the product is, and what regulates it
A chimeric antigen receptor T cell product is made by genetically modifying T cells, from the patient or from a donor, so that they recognize a chosen surface antigen. The receptor combines an antigen-binding portion with intracellular signalling domains. The product administered is a population of living cells, and that single fact is what separates this area from every other modality covered on this site: the material replicates in the recipient, and it is regulated under a different statute.
The regulatory framework, which the original text does not cover
These products are licensed as biologics under Section 351 of the Public Health Service Act and reviewed by the FDA's biologics centre.[S1][S2] They are not approved as new drugs. The application is a Biologics License Application, defined as a request for permission to introduce a biologic product into interstate commerce.[S1] Approved products in this area are listed by the therapeutic products office.[S4] The FDA finalized a guidance specific to this modality in January 2024, covering manufacturing controls, pharmacology and toxicology, and clinical study design, and distinguishing autologous from allogeneic products throughout.[S3] A sponsor starting work here should read that document before designing anything, because it is the only FDA guidance addressing this product type directly.
Approved products
Tisagenlecleucel
The FDA describes this product as a CD19-directed genetically modified autologous T-cell immunotherapy.[S5] Its approval in 2017 was characterized by the FDA at the time as bringing the first gene therapy to the United States, which indicates the level of regulatory attention this modality received from the outset. This article does not state the costimulatory domain used, because the FDA product information consulted for it records the target and the indication but not the construct design.
Axicabtagene ciloleucel
This product is indicated for adult patients with large B-cell lymphoma refractory to first-line chemoimmunotherapy, among other indications.[S6] It addresses the same antigen as the product above. The comparison in the original text, that one construct produces faster expansion and a different cytokine release risk than another, has been removed: it is a comparative claim about approved products, and it could not be verified from the FDA sources used here.
Ciltacabtagene autoleucel
This product is indicated for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.[S7] It is directed at a different antigen from the two above, which matters for nonclinical work in a specific way: the normal tissue expression pattern of the target is what determines the on-target, off-tumour risk, and that assessment has to be done separately for every antigen.
The problems specific to this modality
On-target, off-tumour toxicity and cytokine release
If the target antigen is present on normal cells, the product will attack them, and this is a property of the antigen choice rather than a defect in the construct. It is assessed by mapping expression across normal human tissue before the construct is finalized. Cytokine release and neurological toxicity involve host cells that a modified T cell population recruits. What a nonclinical study can establish here is what the cells do in the systems tested; this article makes no claim that any nonclinical system predicts these syndromes in patients, and the sources consulted did not support one.
Solid tumours
A solid tumour presents obstacles a circulating malignancy does not. The cells have to reach the tumour, enter it, and remain functional inside a suppressive environment. Antigen expression is also uneven across a solid tumour, so cells lacking the antigen are not addressed by the product at all. For study design the consequence is that a model has to permit each of these to be measured separately, since a negative result otherwise cannot be attributed to trafficking, to penetration, to loss of function, or to antigen absence.
The product replicates, so conventional pharmacokinetics does not apply
The FDA guidance on preclinical assessment of these products notes that standard absorption, distribution, metabolism and excretion terminology often does not apply to cell therapy products.[S2] The reason is structural: the administered cells expand when they meet antigen and contract when it is cleared, so the quantity present is a function of the biology rather than of the dose given. What is measured instead is the number of modified cells over time, usually by quantifying the transgene, together with their functional state. Dose and exposure are not related in this modality the way they are elsewhere.
The ICH safety guidances do not apply here, and this is often stated incorrectly
The FDA guidance covering preclinical assessment of cell and gene therapy products states that these products fall outside the scope of the ICH safety guidances, while noting that the basic testing principles in those documents may still be useful as reference.[S8][S2] A CAR T programme described as compliant with the biotechnology-derived pharmaceuticals guidance is therefore describing itself against a framework that does not formally cover it, and that description should carry a qualification. The same guidance sets out where good laboratory practice applies: toxicology studies are conducted under the regulation, while in vitro and in vivo pharmacology and proof-of-concept studies are not required to be.[S2] Getting this boundary right at the planning stage affects cost and timeline materially, because running an exploratory pharmacology study under the full regulation buys nothing the agency asked for.
The nonclinical work
Models that contain the cells the product interacts with
A human cell product requires an animal that will not reject it, which means an immunodeficient host, which in turn means the host lacks the immune cells that participate in cytokine release. That is a genuine conflict rather than a gap to be filled by a better model. Humanized animals reconstituted with human cells address part of it and introduce donor-to-donor variability in exchange. Co-culture systems with tumour spheroids allow the interaction to be observed directly without an animal at all. Whichever is used, the limitation should be recorded in the report rather than left for a reviewer to notice.
Normal tissue cross-reactivity
This is the assessment that most often changes a programme, and it is done against human tissue because the antigen is human. Expression mapping across a normal tissue panel identifies where the antigen occurs; functional testing against cells derived from the tissues of concern establishes whether the product attacks them. Receptor affinity is a design variable here, since a lower-affinity construct may distinguish high-expressing tumour from low-expressing normal tissue that a high-affinity one does not. That trade-off is settled with data, not with a preference.
Tracking the cells and their functional state
Two measurements are needed and they answer different questions. Quantifying the transgene by digital PCR reports how many modified cells are present. Flow cytometry and single-cell sequencing report what state those cells are in, including whether they carry markers of exhaustion. Cells that are present but no longer functional produce the same count as cells that are working, so the count alone is not informative about persistence in any useful sense.
Allogeneic products and genome editing
A donor-derived product raises two questions an autologous one does not: whether the transferred cells attack the recipient, and whether the recipient rejects them. The FDA guidance for this modality distinguishes autologous from allogeneic products throughout, so the two are not interchangeable in a regulatory submission.[S3] Where genome editing is used to make the product, the edits themselves require assessment: off-target cutting is characterized genome-wide, and structural changes such as translocations are looked for, because the concern is a cell that acquires a growth advantage rather than one that fails.
What to establish with the laboratory
Five things are worth establishing before award. Whether the laboratory has worked under the cell and gene therapy framework rather than only the drug framework, since the applicable guidance and the scope of good laboratory practice differ.[S2] What normal tissue panels it holds and whether functional testing against tissue-derived cells is available, not only expression mapping. Whether it quantifies the transgene and assesses functional state as separate measurements. What humanized models it has and how donor variability is handled. And, for an edited product, whether off-target and structural analysis is done in-house or subcontracted, since that affects how the data reaches the submission.[S3]
About this article
This is an independent editorial article for people who commission nonclinical work in the United States. Product descriptions and indications are taken from FDA product information as published, and approvals are recorded as facts; this site does not discuss the efficacy of any product or compare products. Several construct details and one product comparison present in the source material were removed because they could not be verified from the FDA sources used, and those removals are noted in the text. It does not recommend any laboratory. Last reviewed: September 3, 2026.
References
- FDA（CBER）— Biologics License Applications (BLA) Process. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber (accessed 2026-09-03)
- FDA（CBER/OCTGT）— Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products（2013/11）. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/preclinical-assessment-investigational-cellular-and-gene-therapy-products (accessed 2026-09-03)
- FDA（CBER）— Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products（2024/1）. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products (accessed 2026-09-03)
- FDA（CBER/OTP）— Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products (accessed 2026-09-03)
- FDA（CBER）— KYMRIAH product page. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (accessed 2026-09-03)
- FDA（CBER）— YESCARTA product page. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel (accessed 2026-09-03)
- FDA（CBER）— CARVYKTI product page. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/carvykti (accessed 2026-09-03)
- FDA（CDER）— ICH S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6-r1-addendum-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals (accessed 2026-09-03)
Japanese
